Revenues Up Despite Paroxetine Competition And Disappointing Ribavirin Launch, Par Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Par's second quarter revenues jumped despite disappointing revenues from the company's ribavirin generic and lower sales for paroxetine